|Awarded On||August 16, 2017|
|Title||HTS for covalent GTP-competitive inhibitors of KRAS G12C|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Kenneth Westover|
|Cancer Sites||Colorectal, Lung and Bronchus, Pancreas|
RAS mutations are some of the most common genetic abnormalities found in cancerous tumors with 30% of tumors showing RAS mutations, with even higher rates in deadly cancers such as lung, pancreatic and rectal. In normal cells RAS proteins direct cells to grow, divide and survive when appropriate. However, mutant RAS proteins cause cancer by signaling constantly and inappropriately. A number of labs have shown that cancer cells cannot survive after mutant RAS proteins are shut down, but their techniques are only applicable to laboratory settings and therefore cannot be used in patients. Efforts to develop drugs that specifically target RAS-driven cancers have been ongoing for several decades ...